The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation
Open accessAbstract
No specific drugs are currently available against hepatitis delta virus (HDV), a defective virus leading to the most severe form of chronic viral hepatitis in man. The lack of convenient HDV infection models has hampered the development of effective therapeutics. In this study, naïve and hepatitis B virus (HBV) chronically infected humanized uPA/SCID mice were employed to establish a small animal model of HBV/HDV coinfection and superinfection. For preclinical antiviral drug evaluation, the GMP version of the myristoylated preS-peptide (Myrcludex-B), a lipopeptide derived from the pre-S1 domain of the HBV envelope, was applied to prevent de novo HBV/HDV coinfection in vivo . Virological parameters were determined at serological and intrahepatic level both by real-time polymerase chain reaction (PCR) and by immunohistochemistry. Establishment of HDV infection was highly efficient in both HBV-infected and naïve chimeric mice with HDV titers rising up to 1 × 10E9 copies/mL. Notably, HDV superinfection led to a median 0.6log reduction of HBV viremia, which although not statistically significant suggests that HDV may hinder HBV replication. In the setting of HBV/HDV simultaneous infection, a majority of human hepatocytes stained HDAg-positive long before HBV spreading was completed, confirming that HDV can replicate intrahepatically also in the absence of HBV infection. Furthermore, the increase of HBV viremia and intrahepatic cccDNA loads was significantly slower than in HBV mono-infected mice. Treatment with the HBV entry inhibitor Myrcludex-B, efficiently hindered the establishment of HDV infection in vivo . Conclusion : We established an efficient model of HBV/HDV infection to exploit mechanisms of viral interference in human hepatocytes and to test the efficacy of an HDV-entry inhibitor in vivo .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of cccDNA function in hepatitis B virus infection
Levrero, M., Pollicino, T., Petersen, J., Belloni, L., Raimondo, G., & Dandri, M. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.022 · Cited by 552 · cited 1×
“Thus, HDV needs the presence of the HBV minichromosome, the covalently closed circular DNA (cccDNA), which is the template for all HBV RNAs, in the same infected hepatocyte.(12) However, only the HBV envelope proteins (HBsAgs) are required for HDV secretion, and previous clinical studies have indicated that the coexis…”
Background
Cited by
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Bogomolov, P., Alexandrov, A., Voronkova, N., Macievich, M., Kokina, K., Petrachenkova, M., Lehr, T., Lempp, F. A., Wedemeyer, H., Haag, M., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.016 · Cited by 402
Self-citationStrategies to Inhibit Entry of HBV and HDV Into Hepatocytes
Urban, S., Bartenschlager, R., Kubitz, R., & Zoulim, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.030 · Cited by 361
Self-citationHepatitis E virus: advances and challenges
Nimgaonkar, I., Ding, Q., Schwartz, R. E., & Ploss, A. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.150 · Cited by 352
Volz, T., Allweiss, L., ḾBarek, M. B., Warlich, M., Lohse, A. W., Pollok, J. M., Alexandrov, A., Urban, S., Petersen, J., Lütgehetmann, M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.12.008 · Cited by 331
Self-citation
Metadata
- Authors
- Lütgehetmann, M., Mancke, L. V., Volz, T., Helbig, M., Allweiss, L., Bornscheuer, T., Pollok, J. M., Lohse, A. W., Petersen, J., Urban, S., & Dandri, M.
- Venue
- Hepatology
- Published
- 2012-03
- Volume
- 55
- Issue
- 3
- Pages
- 685-694
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2156213027
- Cited by
- 229
- References
- 1
- FWCI
- 10.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.